ES8401486A1
(es)
|
1981-11-10 |
1983-12-01 |
Wellcome Found |
Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina.
|
US4847256A
(en)
|
1986-10-16 |
1989-07-11 |
American Cyanamid Company |
4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
|
AU650953B2
(en)
|
1991-03-21 |
1994-07-07 |
Novartis Ag |
Inhaler
|
US5728536A
(en)
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
US6136595A
(en)
|
1993-07-29 |
2000-10-24 |
St. Jude Children's Research Hospital |
Jak kinases and regulations of cytokine signal transduction
|
US5543523A
(en)
|
1994-11-15 |
1996-08-06 |
Regents Of The University Of Minnesota |
Method and intermediates for the synthesis of korupensamines
|
US5705625A
(en)
|
1994-12-15 |
1998-01-06 |
The Johns Hopkins University School Of Medicine |
Nucleic Acid Encoding novel protein tyrosine kinase
|
US7070972B1
(en)
|
1995-01-13 |
2006-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Janus family kinases and identification of immune modulators
|
EP0842195A1
(fr)
|
1995-07-06 |
1998-05-20 |
Zeneca Limited |
Inhibiteurs peptidiques de la fibronectine
|
US6248713B1
(en)
|
1995-07-11 |
2001-06-19 |
Biogen, Inc. |
Cell adhesion inhibitors
|
US7091020B1
(en)
|
1995-12-05 |
2006-08-15 |
Incyte Corporation |
Human Jak2 kinase
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
US6235741B1
(en)
|
1997-05-30 |
2001-05-22 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
FR2791562B1
(fr)
|
1999-03-29 |
2004-03-05 |
Oreal |
Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
|
YU25500A
(sh)
|
1999-05-11 |
2003-08-29 |
Pfizer Products Inc. |
Postupak za sintezu analoga nukleozida
|
PT1221444E
(pt)
|
1999-07-02 |
2005-11-30 |
Eisai Co Ltd |
Derivados de imidazole condensados e medicamentos para a diabetes mellitus
|
AP1905A
(en)
|
1999-12-10 |
2008-10-20 |
Pfizer Prod Inc |
Pyrrolo[2,3-d] Pyrimidine Compounds.
|
GB0028383D0
(en)
|
2000-11-21 |
2001-01-03 |
Novartis Ag |
Organic compounds
|
EP1241176A1
(fr)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Dérivés de purine pour le traitement de l'ischémie
|
US7199136B2
(en)
|
2001-12-20 |
2007-04-03 |
Bayer Healthcare Ag |
1,4-dihydro-1,4-diphenylpyridine derivatives
|
CA2483306A1
(fr)
|
2002-04-23 |
2003-11-06 |
Shionogi & Co., Ltd. |
Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive
|
US7161003B1
(en)
|
2002-09-04 |
2007-01-09 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US7129239B2
(en)
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
AU2003270701B2
(en)
|
2002-10-31 |
2009-11-12 |
Amgen Inc. |
Antiinflammation agents
|
US7550470B2
(en)
|
2002-12-11 |
2009-06-23 |
Merck & Co. Inc. |
Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
|
JP2006522750A
(ja)
|
2003-04-11 |
2006-10-05 |
ノボ ノルディスク アクティーゼルスカブ |
代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法
|
JP2006522744A
(ja)
|
2003-04-11 |
2006-10-05 |
ノボ ノルディスク アクティーゼルスカブ |
グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
|
US20070270408A1
(en)
|
2003-04-11 |
2007-11-22 |
Novo Nordisk A/S |
Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
|
EP1615697A2
(fr)
|
2003-04-11 |
2006-01-18 |
Novo Nordisk A/S |
Utilisation pharmaceutique de pyrazolo 1,5-a]pyrimidines substituees
|
WO2005004810A2
(fr)
|
2003-07-02 |
2005-01-20 |
Merck & Co., Inc. |
Derives arylsulfonamide
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
SE0302487D0
(sv)
|
2003-09-18 |
2003-09-18 |
Astrazeneca Ab |
Novel compounds
|
GB0329214D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Novel compounds
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
WO2005110477A2
(fr)
|
2004-04-09 |
2005-11-24 |
University Of South Florida |
Polytherapies pour le cancer et des angiopathies proliferantes
|
EP1751159A2
(fr)
|
2004-04-28 |
2007-02-14 |
Cv Therapeutics, Inc. |
Antagonistes du recepteur de l'adenosine a1
|
EP1765825A1
(fr)
|
2004-06-25 |
2007-03-28 |
Amgen Inc. |
Triazols et indazols condenses convenant pour le traitement de maladies induites par les citokines et autres pathologies
|
ES2354824T3
(es)
|
2004-11-04 |
2011-03-18 |
Vertex Pharmaceuticals, Inc. |
Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
|
GB0502258D0
(en)
|
2005-02-03 |
2005-03-09 |
Argenta Discovery Ltd |
Compounds and their use
|
US20100216798A1
(en)
|
2005-07-29 |
2010-08-26 |
Astellas Pharma Inc |
Fused heterocycles as lck inhibitors
|
WO2007039797A1
(fr)
|
2005-10-03 |
2007-04-12 |
Pfizer Products Inc. |
Utilisation d'antagonistes du recepteur cannabinoide de type 1 pour traiter les inflammations et l'arthrite
|
AR057979A1
(es)
|
2005-10-06 |
2008-01-09 |
Schering Corp |
PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
|
EP1931676B1
(fr)
*
|
2005-10-06 |
2011-11-16 |
Schering Corporation |
Pyrazolopyrimidines en tant qu'inhibiteurs de protéines kinases
|
CA2626742A1
(fr)
|
2005-10-21 |
2007-04-26 |
Exelixis, Inc. |
Pyrazolopyrimidines en tant que modulateurs de caseine kinase ii (ck2)
|
CA2629743A1
(fr)
|
2005-12-08 |
2007-06-14 |
Novartis Ag |
Acides pyrazolo[1,5-a]pyridine-3-carboxyliques utilises en tant qu'inhibiteurs de la ephb et vegfr2 kinase
|
US8541406B2
(en)
|
2006-02-07 |
2013-09-24 |
Nv Remynd |
Thiadiazole derivatives for the treatment of neurodegenerative diseases
|
TW200800997A
(en)
|
2006-03-22 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
AR061793A1
(es)
|
2006-07-05 |
2008-09-24 |
Mitsubishi Tanabe Pharma Corp |
Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
EP2089393A1
(fr)
|
2006-10-30 |
2009-08-19 |
Novartis AG |
Composés hétérocycliques en tant qu'agents anti-inflammatoires
|
AU2007321924A1
(en)
|
2006-11-20 |
2008-05-29 |
Alantos Pharmaceuticals Holding, Inc. |
Heterobicyclic metalloprotease inhibitors
|
WO2009017954A1
(fr)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibiteurs de kinase jak2
|
WO2009047359A1
(fr)
|
2007-10-12 |
2009-04-16 |
Ingenium Pharmaceuticals Gmbh |
Inhibiteurs de protéine kinases
|
CN104311563B
(zh)
|
2007-11-28 |
2016-12-07 |
达那-法伯癌症研究所 |
Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法
|
JP2011507910A
(ja)
|
2007-12-21 |
2011-03-10 |
ユニバーシティー オブ ロチェスター |
真核生物の寿命を変更するための方法
|
WO2009155551A1
(fr)
|
2008-06-20 |
2009-12-23 |
Genentech, Inc. |
Composés triazolopyridine inhibiteurs de jak kinase et procédés
|
WO2010019762A1
(fr)
|
2008-08-13 |
2010-02-18 |
Jenrin Discovery |
Composés de purine en tant que bloqueurs de récepteur aux cannabinoïdes
|
SG194397A1
(en)
*
|
2008-10-31 |
2013-11-29 |
Genentech Inc |
Pyrazolopyrimidine jak inhibitor compounds and methods
|
WO2010063487A1
(fr)
|
2008-12-05 |
2010-06-10 |
Merz Pharma Gmbh & Co. Kgaa |
Pyrazolopyrimidines, procédé pour leur préparation et leur utilisation comme médicament
|
AU2010211109B2
(en)
|
2009-02-06 |
2014-11-27 |
Cellzome Limited |
Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
|
TWI461425B
(zh)
|
2009-02-19 |
2014-11-21 |
Janssen Pharmaceuticals Inc |
作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
|
UA110324C2
(en)
*
|
2009-07-02 |
2015-12-25 |
Genentech Inc |
Jak inhibitory compounds based on pyrazolo pyrimidine
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
CA2775009A1
(fr)
|
2009-10-20 |
2011-04-28 |
Cellzome Limited |
Analogues d'heterocyclyl pyrazolopyrimidine en tant qu'inhibiteurs de jak
|
KR20130001272A
(ko)
|
2010-03-17 |
2013-01-03 |
에프. 호프만-라 로슈 아게 |
이미다조피리딘 및 푸린 화합물, 조성물 및 사용 방법
|
KR20130094693A
(ko)
|
2010-04-30 |
2013-08-26 |
셀좀 리미티드 |
Jak 저해제로서의 피라졸 화합물
|
JP5985473B2
(ja)
|
2010-07-13 |
2016-09-06 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
|
WO2012075393A2
(fr)
|
2010-12-02 |
2012-06-07 |
President And Fellows Of Harvard College |
Activateurs de la dégradation protéasomique et leurs utilisations
|
WO2012129258A1
(fr)
*
|
2011-03-22 |
2012-09-27 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
ES2666353T3
(es)
|
2012-09-06 |
2018-05-04 |
Bristol-Myers Squibb Company |
Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias
|
ES2763601T3
(es)
|
2012-11-09 |
2020-05-29 |
Medicines For Malaria Venture Mmv |
Derivados de heteroarilo y sus usos
|
US20160166576A1
(en)
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
BR112016010041B1
(pt)
|
2013-11-08 |
2023-04-18 |
Takeda Pharmaceutical Company Limited |
Composto heterocíclico com uma ação inibitória de irak-4, composição farmacêutica, e, uso do composto
|
WO2015073267A1
(fr)
|
2013-11-15 |
2015-05-21 |
Calitor Sciences, Llc |
Composés hétéroaryle substitués et méthodes d'utilisation
|
JP2017516850A
(ja)
|
2014-05-23 |
2017-06-22 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Jak阻害剤である5−クロロ−2−ジフルオロメトキシフェニルピラゾロピリミジン化合物
|
WO2015179840A1
(fr)
|
2014-05-23 |
2015-11-26 |
Phibro Animal Health Corporation |
Combinaison, composition et méthode d'administration de la combinaison ou de la composition à des animaux
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
US10570135B2
(en)
|
2014-11-06 |
2020-02-25 |
Lysosomal Therapeutics Inc. |
Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders
|
EP3268006B1
(fr)
|
2015-03-12 |
2020-01-08 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de pyrrolotriazine de l'activité d'irak4
|
WO2016144847A1
(fr)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Inhibiteurs à base de pyrrolopyridazine d'activité d'irak4
|
WO2016144844A1
(fr)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Carboxamides utilisés comme inhibiteurs de l'activité de l'irak4
|
EP3267996B1
(fr)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activité d'irak4 à base de pyrazolopyrimidine
|
TW201720828A
(zh)
|
2015-11-23 |
2017-06-16 |
赫孚孟拉羅股份公司 |
治療性化合物及組合物以及其使用方法
|
WO2017140825A1
(fr)
|
2016-02-18 |
2017-08-24 |
F. Hoffmann-La Roche Ag |
Composés thérapeutiques, leurs compositions et méthodes d'utilisation
|
CA3046435A1
(fr)
|
2016-12-29 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Composes pyrazolopyrimidine et leurs procedes d'utilisation
|
CN110494434B
(zh)
|
2017-03-14 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
吡唑并氯苯基化合物、其组合物及其使用方法
|
RU2769696C2
(ru)
*
|
2017-05-22 |
2022-04-05 |
Ф. Хоффманн-Ля Рош Аг |
Терапевтические соединения и композиции и способы их применения
|
JP7228318B6
(ja)
|
2017-05-22 |
2023-03-10 |
エフ. ホフマン-ラ ロシュ アーゲー |
処置用化合物及び組成物、並びにその使用方法
|